FOI 9672 – Q2

In the past 3 months, how many patients have been treated with the following systemic anti-cancer therapies for breast cancer (please indicate whether they were treated for early or metastatic disease):

	Total Patients	Early Patients	Metastatic Patients
Phesgo (Pertuzumab + Trastuzumab in a single injection)	13	6	7
Pertuzumab (Perjeta) + Trastuzumab (Herceptin)	0	0	0
Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel	6	5	<5
Trastuzumab deruxtecan (Enhertu)	9	0	9
Trastuzumab emtansine (Kadcyla)	<5	<5	<5
Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)	25	17	8
Abemaciclib + Fulvestrant	<5	<5	<5
Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)	25	<5	20
Ribociclib + Fulvestrant	<5	0	<5
Capecitabine as a single agent	15	<5	13
Carboplatin + Paclitaxel	0	0	0
Carboplatin + Paclitaxel + Pembrolizumab	6	5	<5